ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
BASF has signed an agreement with Biomillenia that will give it access to the French start-up’s microbiome-on-a-chip technology. BASF says it will use the technology to discover how active ingredients can modulate growth of microbiota on the skin. Biomillenia, a 4-year-old firm whose technology comes from the Broad Institute of MIT and Harvard and École Supérieure de Physique et de Chimie Industrielles de Paris, previously signed research deals with Merck KGaA on vaccine enzymes and with the French firm Soufflet on proteolytic enzymes for animal feed.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter